A Phase 1, Open-label, Non-randomized, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors.
Latest Information Update: 30 Sep 2015
At a glance
- Drugs OPB 51602 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 25 Mar 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jun 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 13 Jun 2012 Planned end date changed from 1 Jul 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov